Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates
Clinical program updates
The Company is currently enrolling patients in the U.S. and
This trial is a multicenter, randomized, double-blind, parallel group, placebo-controlled, 12-week trial to evaluate the efficacy and safety of 32 mg and 64 mg doses of roluperidone as measured by the Positive and Negative Syndrome Scale (PANSS) Marder negative symptoms factor score. The core 12-week study is followed by a 40-week, open-label extension period during which patients on the drug continue receiving their original dose and patients on placebo receive one of the two doses of roluperidone.
In September, 2019, the Company entered into a long-term commercial supply agreement with
Enrollment has been completed in a Phase 2b trial of MIN-117 in the U.S. and
This trial is a 6-week, 3-arm, randomized, double-blind, placebo-controlled study to investigate the safety and efficacy of MIN-117. The primary efficacy endpoint is the change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from baseline (the start of double-blind treatment) to the end of the double-blind treatment period (week 6), and the key secondary endpoint is the change in the Hamilton-Anxiety Rating Scale (HAM-A) over the same period.
During 2019, the Company completed and announced top-line results from three Phase 2b trials and one Phase 1b trial with seltorexant (MIN-202). Three of these trials were in MDD and one was in insomnia disorder.
Key conclusions following data analyses from these trials include the following.
- Seltorexant shows clinically meaningful and consistent improvements in mood and sleep symptoms.
- In depressed patients, seltorexant shows improvement in mood as monotherapy and as add-on therapy to SSRIs or SNRIs, and its effect on mood is stronger in patients with insomnia.
- Among the doses of seltorexant tested, 20 mg shows the most robust and consistent effect on mood.
- In both adult and elderly subjects, seltorexant improves both sleep induction and sleep maintenance compared to zolpidem.
- Seltorexant shows a safety and tolerability profile similar to placebo.
These findings are expected to help define a Phase 3 clinical development program for seltorexant that potentially will encompass both MDD and insomnia.
Third Quarter 2019 Financial Results
- Cash Position: Cash, cash equivalents, marketable securities and restricted cash as of
September 30, 2019were approximately $60.0 million, compared to $88.1 millionas of December 31, 2018.
- R&D Expenses: Research and development (R&D) expenses for the three and nine months ended
September 30, 2019were $9.7 millionand $29.6 million, respectively, compared to $8.4 millionand $25.9 millionfor the same periods in 2018. The increase in R&D expenses primarily reflects higher development expenses for the Phase 3 clinical trial of roluperidone and the Phase 2b clinical trial of MIN-117.
- G&A Expenses: General and administrative (G&A) expenses for the three and nine months ended
September 30, 2019were $4.6 millionand $13.9 million, respectively, compared to $4.1 millionand $12.2 millionfor the same periods in 2018. The increase in G&A expenses during the three-month period was primarily due to higher professional fees to support pre-commercial activities. The increase in G&A expenses during the nine-month period was primarily due to an increase in non-cash stock-based compensation expenses, increased salary costs and professional fees to support pre-commercial activities.
- Net Loss: The Company reported a net loss for the three and nine months ended
September 30, 2019of $14.0 millionand $42.3 millionrespectively, or $0.36and $1.08per share, respectively, compared to $12.0 millionand $37.0 million, respectively, or $0.31and $0.95per share, respectively, for the same period in 2018.
Conference Call Information:
The live webcast can be accessed under “Events and Presentations” in the Investors and Media section of Minerva’s website at ir.minervaneurosciences.com. The archived webcast will be available on the website beginning approximately two hours after the event for 90 days.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and scope of future clinical trials and results of clinical trials with roluperidone, seltorexant, MIN-117 and MIN-301; the clinical and therapeutic potential of these compounds; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management’s ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether roluperidone, seltorexant, MIN-117 and MIN-301 will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the
|CONDENSED CONSOLIDATED BALANCE SHEET DATA
|September 30,||December 31,|
|Cash and cash equivalents||$||37,906||$||50,235|
|Prepaid expenses and other current assets||1,377||1,921|
|Total current assets||61,410||90,019|
|Other noncurrent assets||15||15|
|Operating lease right-of-use assets||299||-|
|In-process research and development||34,200||34,200|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accrued expenses and other current liabilities||4,398||1,810|
|Total current liabilities||9,895||3,609|
|Other noncurrent liabilities||-||29|
|Noncurrent operating leases||157||-|
|Additional paid-in capital||312,342||304,814|
|Total stockholders' equity||55,528||90,265|
|Total Liabilities and Stockholders' Equity||$||110,813||$||139,136|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
|Three Months Ended September 30,
||Nine Months Ended September 30,
|(in thousands, except per share amounts)
||(in thousands, except per share amounts)
|Research and development||9,674||8,369||29,600||25,881|
|General and administrative||4,608||4,055||13,898||12,221|
|Total operating expenses||14,282||12,424||43,498||38,102|
|Foreign exchange losses||(5||)||(11||)||(18||)||-|
|Loss before income taxes||(13,962||)||(12,021||)||(42,266||)||(36,968||)|
|Benefit for income taxes||-||-||-||-|
|Net (loss) income||$||(13,962||)||$||(12,021||)||$||(42,266||)||$||(36,968||)|
|Loss per share:|
|Basic and diluted||$||(0.36||)||$||(0.31||)||$||(1.08||)||$||(0.95||)|
|Weighted average shares:|
|Basic and diluted||39,025||38,782||39,007||38,760|
VP, Investor Relations/
Source: Minerva Neurosciences, Inc